limit
word
novel
human
coronaviru
first
discov
citi
wuhan
hubei
provinc
china
caus
outbreak
pneumonia
januari
april
viru
rapidli
dissemin
countri
territori
caus
million
confirm
case
death
worldwid
clinic
present
fairli
nonspecif
symptom
overlap
season
respiratori
infect
concurr
circul
popul
estim
infect
individu
experi
mild
symptom
asymptomat
confound
effort
reliabl
diagnos
empir
support
infect
control
measur
urgent
need
rapid
accur
molecular
diagnost
identifi
posit
patient
present
studi
evalu
analyt
sensit
clinic
perform
four
molecular
diagnost
assay
grant
emerg
use
author
fda
use
nasopharyng
swab
symptomat
patient
inform
crucial
laboratori
clinic
team
decis
test
platform
implement
made
rna
intern
control
probe
use
detect
rtpcr
failur
andor
inhibit
result
interpret
algorithm
report
posit
specimen
requir
one
two
target
detect
gene
genmark
eplex
eua
panel
test
eplex
panel
perform
accord
manufactur
instruct
use
briefli
vortex
second
primari
np
sampl
aspir
sampl
deliveri
devic
sdd
provid
eplex
panel
kit
vortex
second
entir
volum
sdd
dispens
sampl
load
port
test
cartridg
follow
firmli
push
cap
secur
seal
sampl
deliveri
port
cartridg
barcod
scan
eplex
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
intern
control
ic
ad
test
specimen
control
via
work
panther
fusion
captur
reagent
wfcr
hybrid
nucleic
acid
separ
specimen
magnet
field
wash
step
elut
step
occur
output
purifi
rna
elut
nucleic
acid
transfer
panther
fusion
reaction
tube
alreadi
contain
oil
reconstitut
mastermix
panther
assay
amplifi
detect
two
conserv
region
gene
fluoresc
channel
two
region
differenti
amplif
either
region
lead
fluoresc
rox
signal
result
interpret
algorithm
report
posit
specimen
requir
one
two
target
detect
gene
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
analyt
sensit
per
claim
copi
ml
copi
ml
copi
ml
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
cohen
kappa
valu
also
calcul
measur
overal
agreement
valu
categor
almostperfect
strong
moder
weak
minim
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
none
probit
analys
use
copiesml
determin
analyt
sensit
studi
doserespons
percentil
confid
interv
ci
model
assess
use
finney
steven
calcul
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
analyt
sensit
serial
dilut
panel
control
test
determin
lod
defin
minimum
concentr
detect
posit
rate
probit
analysi
lod
establish
percent
posit
rate
rang
copiesml
genmark
modifi
cdc
assay
copiesml
diasorin
molecular
assay
tabl
lod
result
subject
probit
analysi
detect
limit
cdc
assay
copiesml
gene
copiesml
gene
diasorin
molecular
assay
detect
limit
copiesml
gene
copiesml
holog
assay
detect
limit
copiesml
probit
analysi
could
perform
genmark
assay
tabl
final
lod
accord
assay
result
interpret
algorithm
manufactur
rang
copiesml
genmark
assay
copiesml
diasorin
molecular
assay
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
detail
discord
sampl
analysi
shown
tabl
total
five
discord
sampl
found
among
three
four
platform
one
fals
posit
sampl
ct
valu
gene
respect
initi
test
modifi
cdc
assay
repeat
extract
retest
sampl
determin
neg
two
sampl
consid
fals
neg
genmark
posit
three
method
reprocess
retest
genmark
assay
abl
detect
sampl
posit
two
addit
fals
posit
sampl
found
holog
assay
origin
sampl
retest
found
posit
neg
respect
follow
retest
five
discord
sampl
genmark
eplex
eua
panel
show
improv
sensit
addit
specif
obtain
cdc
assay
holog
improv
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
tabl
hot
rang
platform
longest
time
holog
assay
hour
follow
modifi
cdc
assay
hour
minut
compar
hot
found
diasorin
molecular
genmark
rang
minut
minut
respect
run
time
averag
minut
modifi
cdc
diasorin
molecular
genmark
holog
except
hour
min
run
time
tabl
overal
turnaround
time
assess
sampl
result
show
diasorin
molecular
least
overal
turnaround
time
result
follow
genmark
modifi
cdc
assay
holog
greatest
overal
time
tabl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
data
suggest
four
pcr
method
yield
compar
result
howev
observ
notabl
differ
sensit
method
largescal
evalu
eua
vitro
diagnost
assay
studi
show
diasorin
molecular
holog
fusion
assay
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
perform
modifi
cdc
genmark
assay
came
overal
lod
genmark
overal
highest
lod
four
platform
evalu
diasorin
molecular
lowest
lod
copiesml
close
follow
holog
copiesml
modifi
cdc
assay
show
final
lod
copiesml
base
result
interpret
algorithm
worth
mention
assay
requir
target
fulli
detect
thu
clinic
sampl
fall
concentr
rang
would
identifi
repeat
potenti
gener
addit
turnaround
time
laboratori
labor
contrast
genmark
could
detect
replic
copiesml
abl
reliabl
detect
replic
copiesml
thu
patient
specimen
concentr
rang
could
potenti
miss
one
import
limit
mention
sensit
use
probit
analysi
could
calcul
genmark
sinc
ct
valu
avail
part
eplex
system
result
interpret
clinic
correl
also
consist
lod
find
diasorin
molecular
holog
assay
sensit
detect
specimen
deem
posit
consensu
standard
interpret
three
four
evalu
assay
gold
standard
wherea
genmark
miss
two
posit
specimen
subsequ
detect
genmark
upon
repeat
diasorin
molecular
genmark
show
specif
holog
cdc
assay
initi
two
one
discord
result
respect
repeat
test
three
specimen
show
holog
repeat
posit
second
time
therefor
potenti
fals
posit
neg
upon
repeat
mean
result
could
previous
fals
posit
well
continu
discord
result
could
potenti
attribut
specif
issu
sinc
assay
prove
sensit
assay
among
use
studi
diasorin
molecular
show
slightli
lower
lod
repeat
test
modifi
cdc
assay
neg
consid
lod
modifi
cdc
assay
coupl
fact
diasorin
molecular
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
come
handson
turnaround
time
four
assay
studi
throughput
workflow
evalu
clearli
shown
tabl
base
lab
technologist
experi
laboratori
routin
realtim
rtpcr
assay
modifi
cdc
requir
nucleic
acid
extract
master
mix
prepar
pcr
setup
standard
pcr
amplif
well
interpret
purchas
addit
instrument
allow
test
sampl
time
order
satisfi
patient
test
volum
requir
holog
panther
fusion
platform
autom
workflow
five
sampl
process
time
load
sampl
answer
time
first
five
sampl
hour
min
follow
result
everi
minut
load
sampl
total
assay
run
time
specimen
approxim
hour
min
also
import
note
holog
platform
longer
handson
time
sinc
technologist
load
primer
probe
consum
fact
clinic
sampl
manual
transfer
sampl
lysi
buffer
tube
step
especi
pipet
specimen
lysi
tube
somewhat
labor
intens
time
consum
bump
overal
turnaround
time
specimen
closer
hour
mark
import
emphas
platform
advantag
workflow
tat
eas
use
three
sampletoansw
platform
diasorin
molecular
holog
genmark
perform
modifi
cdc
assay
manual
assay
requir
mani
step
special
personnel
